Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Donepezil/memantine extended release

Drug Profile

Donepezil/memantine extended release

Alternative Names: ADS-8703; ADS-8704; Arimenda; donepezil HCl/memantine ER; donepezil HCl/Namenda XR®; MDX-8704; memantine ER/donepezil HCl; memantine ER/donepezil IR; Namenda XR®/donepezil HCl; Namzaric

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adamas Pharmaceuticals
  • Developer Adamas Pharmaceuticals; Allergan
  • Class Analgesics; Antidementias; Antiparkinsonians; Antispastics; Indans; Nootropics; Organic bridged compounds; Piperidines; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Alzheimer's disease
  • No development reported Dementia

Most Recent Events

  • 22 Sep 2016 Allergan and Adamas Pharmaceuticals launch new dosage strengths of Donepezil/memantine extended release in USA
  • 19 Jul 2016 The US FDA approves expanded indication for donepezil/memantine for the treatment of patients with Alzheimer's disease (Moderate-to-severe) stabilised on donepezil monotherapy
  • 18 May 2015 Launched for Alzheimer's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top